Phase I clinical trials have been initiated to investigate the efficacy of these IVT CAR T cells redirected for mesothelin (CARTmeso cells) in malignant pleural mesothelioma patients and other tumors that overexpress mesothelin [48]. Here, MSLN is linked to malignant pleural mesothelioma.